Wide Ranks

DHR

Danaher Corporation

238.83

Top Statistics
Market Cap 172 B Forward PE 28.39 Revenue Growth 3.10 %
Current Ratio 1.37 Trailing PE 45.06 Earnings Growth -26.00 %
Profit Margins 16.39 % Peg Ratio Dividend Yield 0.45 %
Enterprice / EBITA 25.12 Enterprise / Revenue 7.95 Price To Sales Trailing12 Months 7.27
Profitability
Profit Margins 16.39 % Operating Margins 20.34 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 3.64 Total Debt 18 B
Total Debt To Equity 36.69 Current Ratio 1.37 Book Value Per Share 71.03
All Measures
Return On Equity 0.0759 Total Debt 18 B Beta 0.8810
Last Split Date 1 B Fifty Two Week Low 215.68 Target Mean Price 290.13
Short Percent Of Float 0.0079 Trailing Peg Ratio 318.92 % Last Fiscal Year End 1 B
Average Volume10days 3 M Next Fiscal Year End 1 B Held Percent Insiders 0.1100
Ebitda Margins 31.64 % Trailing PE 45.06 Most Recent Quarter 1 B
Gmt Off Set Milliseconds -18000000 Fifty Day Average 256.00 Open 237.25
State DC Return On Assets 0.0386 Time Zone Short Name EST
Trailing Eps 5.30 Day Low 235.67 Shares Outstanding 722 M
Price Hint 2 Website https://www.danaher.com 52 Week Change 0.0695
Recommendation Key buy Quick Ratio 91.60 % Last Split Factor 1128:1000
Is_sp_500 True Profit Margins 16.39 % Debt To Equity 36.69
Fifty Two Week High 281.70 Enterprise To Revenue 7.95 Operating Cashflow 6 B
Five Year Avg Dividend Yield 37.00 % Market Cap 172 B Quote Type EQUITY
Industry Diagnostics & Research Ex Dividend Date 1 B Long Name Danaher Corporation
Current Ratio 1.37 Number Of Analyst Opinions 24 Forward PE 28.39
Regular Market Volume 2 M Short Ratio 165.00 % Message Board Id finmb_265621
Fax 202 828 0860 Shares Short Prior Month 5 M City Washington
Uuid 295d410e-b8c1-3fcf-8a32-c618d752812e Previous Close 236.58 First Trade Date Epoch Utc 283 M
Book Value 71.03 Volume 2 M Price To Book 3.36
Total Cash Per Share 3.64 Total Revenue 23 B Shares Short Previous Month Date 1 B
Target Median Price 286.55 Max Age 86400 Recommendation Mean 1.58
Sand P52 Week Change 0.3133 Operating Margins 20.34 % Last Dividend Value 0.2700
Net Income To Common 3 B Ask 239.64 Implied Shares Outstanding 722 M
Average Daily Volume10 Day 3 M Total Cash 2 B Revenue Per Share 32.29
Dividend Rate 1.08 Date Short Interest 1 B Regular Market Previous Close 236.58
Target Low Price 255.00 Free Cashflow 5 B Dividend Yield 0.45 %
Target High Price 315.00 Address1 2200 Pennsylvania Avenue, North West Trailing Annual Dividend Rate 1.05
Average Volume 2 M Earnings Quarterly Growth -27.50 % Forward Eps 8.38
Compensation As Of Epoch Date 1 B Regular Market Day High 240.94 Day High 240.94
Shares Short 5 M Regular Market Open 237.25 Industry Key diagnostics-research
Bid 238.45 Earnings Growth -26.00 % Revenue Growth 3.10 %
Shares Percent Shares Out 0.0070 Currency USD Time Zone Full Name America/New_York
Is_nasdaq_100 False Zip 20037-1701 Payout Ratio 24.91 %
Regular Market Day Low 235.67 Held Percent Institutions 0.8139 Current Price 238.83
Address2 Suite 800 West Enterprise To Ebitda 25.12 Trailing Annual Dividend Yield 0.44 %
Financial Currency USD Gross Margins 59.87 % Industry Disp Diagnostics & Research
Country United States Float Shares 641 M Two Hundred Day Average 256.39
Ir Website http://phx.corporate-ir.net/phoenix.zhtml?c=82105&p=irol-irhome Enterprise Value 188 B Price To Sales Trailing12 Months 7.27
Last Dividend Date 1 B Ebitda 7 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.

The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products.

This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings.

The company has a research  collaboration  with Stanford  University's Department  of  Bioengineering for cancer drug development.

The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.

Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.